Late Gadolinium Enhancement (LGE)
Definition
Late gadolinium enhancement (LGE) is a cardiac MRI technique that detects regions of myocardial fibrosis, scarring, or infiltration. Gadolinium contrast accumulates in areas with expanded extracellular matrix (fibrosis) or cell death, appearing as bright signal on inversion-recovery T1-weighted sequences acquired 5–20 minutes post-injection. LGE is distinct from ischaemic scar (subendocardial/transmural) — non-ischaemic LGE has characteristic distribution patterns that carry strong aetiological and prognostic implications in cardiomyopathies.
Key Concepts
Diagnostic Role Across Cardiomyopathy Phenotypes
- HCM: LGE present in ~65% of patients; typically patchy mid-wall in areas of hypertrophy and at RV insertion points. Extensive LGE (≥15% of LV mass) is associated with 2.32-fold increased SCD risk and is used in shared decision-making for ICD implantation. (sources/esc-cmp-2023)
- DCM: Lateral wall epicardial LGE suggests dystrophinopathy; subepicardial/mid-wall LGE at basal septum ± inferolateral extension suggests sarcoidosis; apical transmural LGE suggests Chagas disease. (sources/esc-cmp-2023)
- NDLVC: LGE confirmation of non-ischaemic fibrosis is essential for diagnosis. Genotype-specific patterns: ring-like/subepicardial (DSP, FLNC, PLN); septal mid-wall (LMNA); heterogeneous/less scar (TTN, BAG3, DMD, RBM20). (sources/esc-cmp-2023)
- ARVC: Fat and LGE (transmural RV + subepicardial–mid-mural LV free wall) in desmosomal variants. CMR is the only tool allowing detection of LV involvement in ARVC. (sources/esc-cmp-2023)
- RCM: Partial LV or RV apical obliteration + endocardial LGE suggests endomyocardial fibrosis/hypereosinophilia. (sources/esc-cmp-2023)
- Anderson-Fabry disease: Basal-posterolateral/inferolateral LGE + low native T1 (pathognomonic combination). (sources/esc-cmp-2023)
- Cardiac amyloidosis: Diffuse subendocardial LGE (more prevalent in AL) or transmural LGE (more prevalent in ATTR); biventricular transmural in advanced disease; basal predilection. PSIR technique mandatory — standard mag-IR cannot reliably null the myocardium due to ECV expansion approaching plasma volume. LGE sensitivity 85–90%, specificity ~92% (meta-analysis, 7 studies). Partially protein-bound agents (gadolinium-BOPTA/MultiHance) must not be used. (sources/esc-cmp-2023, sources/imaging-amyloidosis-aha-2021)
Prognostic Role
- In HCM, LGE ≥15% LV mass is associated with 2.32-fold increased risk of SCD/aborted SCD/appropriate ICD discharge (meta-analysis, n≈3000). (sources/esc-cmp-2023)
- In DCM and NDLVC, LGE burden influences ICD threshold decisions — high-risk genotype + LGE is a Class IIa indication for primary prevention ICD even with LVEF >35%. (sources/esc-cmp-2023)
- In DCM specifically, LGE is the strongest single VA predictor: pooled HR 5.55 [4.02–7.67] across 8 studies in the largest VA-specific DCM meta-analysis (n=11,451). All eight pooled studies showed consistent direction of effect. The combination of LGE + QRS ≥120 ms had HR 9.53 [2.84–31.98] in one study, suggesting additive risk. (sources/VA-DCM-Sammani-2020)
- In ARVC, LGE on CMR identifies LV involvement that Task Force Criteria underestimate. (sources/esc-cmp-2023)
Ischaemic Viability Assessment
- Transmural extent of LGE is the primary CMR viability tool in chronic CAD with LV dysfunction — predicts stepwise decreasing likelihood of segmental contractile recovery after revascularization (Kim et al., NEJM 2000). (sources/imaging-viability-aha-2020, rating: very high)
- No/minimal LGE: >90% probability of contractile recovery after successful revascularization.
- 26–50% transmural LGE: intermediate; combined with dobutamine contractile reserve assessment.
-
50% transmural LGE: <10% probability of recovery despite successful revascularization.
- LGE-CMR diagnostic performance for viability (meta-analysis, 24 CMR studies, n=331): sensitivity 95%, specificity 51%, PPV 69%, NPV 90% for predicting segmental functional recovery after revascularization. Highest sensitivity and NPV of all imaging modalities tested. (sources/imaging-viability-aha-2020, rating: very high)
- Complementary role with dobutamine CMR: LGE provides highest sensitivity; dobutamine contractile reserve provides highest specificity (91%) and PPV (93%). Combined LGE + dobutamine reserve improves overall accuracy. (sources/imaging-viability-aha-2020, rating: very high)
- Wall thinning alone is insufficient: EDWT <5.5 mm has 94% sensitivity but only 52% specificity for viability; ~20% of thinned segments without LGE recover contractile function after revascularization (Shah et al., JAMA 2013). (sources/imaging-viability-aha-2020, rating: very high)
- Dark-blood LGE technique: Increasingly used at experienced centres to improve subendocardial MI detection where standard bright-blood LGE may miss thin infarct layers due to suboptimal blood-to-scar contrast. (sources/imaging-viability-aha-2020, rating: very high)
Post-MI Scar Detection — ECG Limitations and Electrically Silent Infarcts
- In reperfused STEMI patients, 23–44% have non-diagnostic ECGs by ESC/ACCF/AHA/WHF Q-wave criteria over 5-year follow-up — LGE-CMR confirms persistent irreversible scar in all cases, demonstrating that Q-wave regression is pseudo-normalization, not true healing. (sources/qwave-mri-jacc-imaging-2012, rating: high)
- Q-wave presence is determined primarily by infarct size, not transmurality: a relative infarct size ≥6.2% LV mass at 1 year predicts a diagnostic ECG with 89% sensitivity and 74% specificity (AUC 0.85). Anterior infarcts are reliably detected by ECG; nonanterior (inferior/lateral) infarcts are disproportionately electrically silent. (sources/qwave-mri-jacc-imaging-2012, rating: high)
- Electrically silent MIs carry equivalent prognosis to overt Q-wave MIs — LGE-CMR is the recommended technique to detect myocardial damage in patients with suspected previous MI and non-diagnostic ECG, particularly for nonanterior territories. (sources/qwave-mri-jacc-imaging-2012, rating: high)
- See concepts/Q-Wave-Remodeling for the full framework.
Technical Considerations
- Contrast-enhanced CMR recommended at initial evaluation (Class I, Level B) and serial follow-up every 2–5 years. (sources/esc-cmp-2023)
- The 2-SD threshold is the only LGE quantification method validated against necropsy in HCM. (sources/esc-cmp-2023)
- CMR can be safely performed with most cardiac implantable electronic devices using appropriate protocols. (sources/esc-cmp-2023)
- Gadolinium should be avoided in pregnancy and used with caution in severe renal impairment (eGFR <30 mL/min/1.73m²). (sources/esc-cmp-2023)
- T1 mapping (native and post-contrast) and ECV quantification provide additional tissue characterization and are particularly useful for Anderson-Fabry disease and amyloidosis. (sources/esc-cmp-2023)
- In cardiac amyloidosis specifically: PSIR (phase-sensitive inversion recovery) technique is mandatory — standard mag-IR cannot reliably null the myocardium (ECV expands to approach plasma volume, nulling both simultaneously). TI scout confirms this: myocardium nulls before blood pool = pathognomonic. Partially protein-bound contrast agents (gadolinium-BOPTA/MultiHance) must not be used as they render ECV and LGE pattern unreliable. ECV >0.40 is highly suggestive of cardiac amyloidosis and is elevated even before LGE is apparent, making it an early disease marker. (sources/imaging-amyloidosis-aha-2021)
Atrial LGE — Fibrosis Detection in Atrial Cardiomyopathy
- CMR-LGE can detect atrial fibrosis as part of the ESC/HFA 2025 AtCM diagnostic framework; LA LGE ≥10–15% is proposed as the threshold for "excessive atrial fibrosis" that contributes to an AtCM diagnosis when combined with electrical atrial dysfunction. (sources/atrial-cmp-esc-2025, rating: high)
- Small studies suggest LA LGE ≥10–15% predicts: incident atrial arrhythmias, ischaemic stroke, and arrhythmia recurrence after pulmonary vein isolation. However, further research is warranted before widespread clinical adoption.
- Critical limitation: Current CMR spatial resolution is limited relative to the thin atrial wall (~2–3 mm). Multiple acquisition and post-processing protocols differ substantially in the amount and regional distribution of detected LA fibrosis — LGE percentages are not comparable across centres. (sources/atrial-cmp-esc-2025, rating: high)
- Histological validation gap: It remains unclear whether CMR-detected atrial LGE primarily identifies large areas of replacement fibrosis or is also sensitive to reactive (endomysial and perimysial) fibrosis — these have distinct arrhythmogenic implications.
- LASr <23% correlates with histological atrial fibrosis burden in advanced HF — echocardiographic strain may serve as a practical surrogate where atrial CMR is technically limited. (sources/atrial-cmp-esc-2025, rating: high)
- See concepts/Atrial-Cardiomyopathy for the full AtCM diagnostic framework.
Cardio-Oncology Applications
- ICI myocarditis: LGE and T2-weighted STIR on CMR are diagnostic criteria for ICI-associated myocarditis; native T1 elevation in 136 patients with suspected ICI myocarditis was highly predictive of future MACE. (sources/ai-cardiooncology-aha-2025, rating: high)
- T1/T2 mapping in ICI myocarditis: Native T1 and T2 are used as prognostic biomarkers — not just LGE — in the ICI myocarditis setting, extending their role beyond structural cardiomyopathies. (sources/ai-cardiooncology-aha-2025)
- Ibrutinib cardiotoxicity: Increased native T1/T2 by CMR was highly predictive of future MACE in haematologic malignancy patients on ibrutinib. (sources/ai-cardiooncology-aha-2025)
- CMR-derived ECV, native T1/T2, and LGE predict survival outcomes and can guide treatment in cardiac amyloidosis. (sources/ai-cardiooncology-aha-2025)
Contradictions / Open Questions
- LGE quantification method — no consensus standard: Multiple LGE quantification methods exist (2-SD, 5-SD, full-width half-maximum, visual). Only the 2-SD method has been validated against necropsy in HCM; other methods are widely used in published studies but produce different absolute LGE values. The ≥15% threshold for elevated SCD risk is inconsistently applicable across methods, yet guidelines apply it without specifying quantification technique. (sources/esc-cmp-2023, sources/HCM-AHA-2024)
- Periodic CMR for SCD surveillance — cost and capacity: AHA 2024 recommends periodic CMR every 3–5 years for longitudinal SCD risk surveillance (Class IIb). ESC 2023 also recommends serial CMR every 2–5 years. In countries with limited CMR capacity or high out-of-pocket costs, systematic implementation is impractical for the majority of HCM patients. The recommendation assumes infrastructure that does not universally exist. (sources/HCM-AHA-2024, sources/esc-cmp-2023)
Connections
- Related to concepts/Atrial-Cardiomyopathy — atrial LGE ≥10–15% as fibrosis criterion; spatial resolution limitation
- Related to concepts/Myocardial-Viability
- Related to sources/imaging-viability-aha-2020
- Related to entities/HCM
- Related to entities/DCM
- Related to entities/NDLVC
- Related to entities/ARVC
- Related to entities/Anderson-Fabry-Disease
- Related to entities/ATTR-Amyloidosis
- Related to entities/DSP
- Related to entities/LMNA
- Related to entities/PLN
- Related to concepts/HCM-Risk-SCD
- Related to concepts/Phenotypic-Approach-to-Cardiomyopathy
- Related to concepts/VA-Risk-Stratification-DCM
- Related to concepts/Cardiac-Amyloidosis-Imaging
- Related to concepts/Cancer-Therapy-Related-CV-Toxicity
- Related to sources/ai-cardiooncology-aha-2025
- Related to concepts/Q-Wave-Remodeling
- Related to sources/qwave-mri-jacc-imaging-2012